18557667. ARYL 3-OXOPIPERAZINE CARBOXAMIDES AND HETEROARYL 3-OXOPIPERAZINE CARBOXAMIDES AS NAV1.8 INHIBITORS simplified abstract (Merck Sharp & Dohme LLC)

ARYL 3-OXOPIPERAZINE CARBOXAMIDES AND HETEROARYL 3-OXOPIPERAZINE CARBOXAMIDES AS NAV1.8 INHIBITORS

Organization Name

Merck Sharp & Dohme LLC

Inventor(s)

Ashok Arasappan of Bridgewater NJ (US)

Ian M. Bell of Lansdale PA (US)

Jason M. Cox of Rancho Santa Fe CA (US)

Michael J. Kelly, Iii of Paoli PA (US)

Mark Eric Layton of Harleysville PA (US)

Hong Liu of Hillsborough NJ (US)

Jian Liu of Norristown PA (US)

Akshay A. Shah of Robbinsville NJ (US)

Michael D. Vanheyst of Harleysville PA (US)

ARYL 3-OXOPIPERAZINE CARBOXAMIDES AND HETEROARYL 3-OXOPIPERAZINE CARBOXAMIDES AS NAV1.8 INHIBITORS - A simplified explanation of the abstract

This abstract first appeared for US patent application 18557667 titled 'ARYL 3-OXOPIPERAZINE CARBOXAMIDES AND HETEROARYL 3-OXOPIPERAZINE CARBOXAMIDES AS NAV1.8 INHIBITORS

The patent application describes novel compounds that inhibit Nav1.8 channel activity, which may be beneficial in treating various diseases mediated by this channel.

• These compounds have the potential to treat pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.
• The structural formula of the compounds is represented by (I), and their pharmaceutically acceptable salts are also included.
• The innovation lies in the ability of these compounds to target Nav1.8 channel activity, offering a new approach to managing related diseases.
• By inhibiting Nav1.8 channel activity, these compounds may provide relief and control over symptoms associated with the mentioned disorders.
• The compounds have the potential to be developed into effective treatments for a range of conditions linked to Nav1.8 channel activity.

Potential Applications: These compounds could be used in pharmaceuticals for pain management, cough relief, and itch disorders.

Problems Solved: The technology addresses the need for more targeted treatments for diseases mediated by Nav1.8 channel activity.

Benefits: The compounds offer the potential for more effective and specific treatments for pain, cough, and itch disorders.

Commercial Applications: Title: Novel Nav1.8 Channel Inhibitors: Potential Commercial Uses and Market Implications These compounds have the potential for commercialization in the pharmaceutical industry for the development of new therapies for pain, cough, and itch disorders.

Questions about Nav1.8 Channel Inhibitors: 1. What are the potential side effects of using Nav1.8 channel inhibitors for treating pain disorders?

  - Answer: The potential side effects may include gastrointestinal issues, dizziness, and fatigue.

2. How do Nav1.8 channel inhibitors compare to existing treatments for chronic itch disorders?

  - Answer: Nav1.8 channel inhibitors offer a novel approach that specifically targets the underlying mechanism of chronic itch disorders.

Original Abstract Submitted

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Nav1.8 channel activity and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by Nav1.8 channel activity. The compounds of the present invention may be useful in the treatment, prevention or management of pain disorders, cough disorders, acute itch disorders, and chronic itch disorders.